

**17th WHO EXPERT COMMITTEE ON THE SELECTION AND
USE OF ESSENTIAL MEDICINES**

WHO headquarters, Geneva, Room M-505, 23-27 March 2009

DRAFT AGENDA

1. Applications for addition of medicines to the WHO Model List

- Amantadine and rimantadine
- Amiodarone
- Antipsychotic and antidepressive medicines
- Carboplatin
- Endar
- Escitalopram oxalate
- Hydroxycarbamide
- Ifosfamide
- Lamotrigine
- Lorazepam
- Mesna
- Midazolam
- Misoprostol
- Nicotine Replacement Therapy (NRT)
- Nifurtimox + eflornithine
- Omeprazole
- Oseltamivir
- Paroxetine hydrochloride
- Pralidoxime
- Rifabutin
- Sertraline hydrochloride
- Sumatriptan
- Tranexamic acid
- Zanamivir

2. Applications for additional medicine formulations

- Beclometasone
- Hydrochlorothiazide

3. Application for re-instatement of a medicine to the WHO Model List

- Cromoglicic acid

4. Application for deletion of a medicine from the WHO Model List

- Quinidine

5. Section review

- Protease inhibitors

6. Paediatric medicines

- Draft Report of the Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines
- Draft Second Essential Medicines List for Children
- Discussion of the document "*Access to Essential Diabetes Medicines for Children in the Developing World*"
- Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children, WHO headquarters, Geneva, Switzerland, 15-16 December 2008
- Artemether + lumefantrine (Inclusion)
- Captopril (Inclusion)
- Carvedilol (Inclusion)
- Comments from Dr D. Fuller on fluoroquinolones in children
- Ibuprofen (Inclusion)
- Liposomal amphotericin B (Inclusion)
- Request for deletion of ciprofloxacin from 6.2.2 Other antibacterials

7. Other matters